Literature DB >> 18559598

Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.

Inti Zlobec1, Luigi M Terracciano, Alessandro Lugli.   

Abstract

PURPOSE: The identification of colon cancer patients at high risk of local recurrence is necessary to improve the selection of patients for more tailored treatment protocols. The aim of this study was to develop a predictive model of local recurrence by assessing the independent predictive effect of 7 clinicopathologic features, 24 protein markers of tumor progression, and their multifeature combinations in mismatch repair-proficient colon cancers. EXPERIMENTAL
DESIGN: Immunohistochemistry for 24 protein markers was done on 269 patients with complete clinicopathologic data. After univariate and multivariable analyses, independent predictors of local recurrence were identified and their multifeature combinations were analyzed. Kaplan-Meier and Cox proportional hazards regression were done for survival analysis.
RESULTS: Local recurrence was observed in 119 patients (55.8%). Independent predictors of tumor recurrence were lymph node involvement (P = 0.006), absence of CD8+ tumor-infiltrating lymphocytes (TIL; P < 0.001), and infiltrative tumor margin (P < 0.001). This independent effect persisted after adjusting for adjuvant therapy. Risk of recurrence was 0.75 and the 5-year survival rate was 8.8% in patients with these three adverse features. Node-negative patients with an infiltrative tumor margin and absence of CD8+ TILs were identified as high risk with a probability of 0.55 for recurrence and a 60% 5-year survival rate. The remaining node-negative cases fared significantly better with risks ranging from 8% to 26% and 5-year survival rates reaching 97.6%.
CONCLUSIONS: An infiltrative tumor margin and absence of CD8+ TILs are highly predictive of local recurrence in node-negative mismatch repair-proficient colon cancer and may help to identify high-risk patients who may benefit from adjuvant chemotherapy.

Entities:  

Mesh:

Year:  2008        PMID: 18559598     DOI: 10.1158/1078-0432.CCR-08-0048

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery.

Authors:  Koichiro Mori; Yuji Toiyama; Susumu Saigusa; Hiroyuki Fujikawa; Junichiro Hiro; Minako Kobayashi; Masaki Ohi; Toshimitsu Araki; Yasuhiro Inoue; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

Review 2.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

Review 3.  The immune response in cancer: from immunology to pathology to immunotherapy.

Authors:  Nicolas A Giraldo; Etienne Becht; Yann Vano; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2015-06-16       Impact factor: 4.064

Review 4.  Metastasis-suppressor genes in clinical practice: lost in translation?

Authors:  Alexander N Shoushtari; Russell Z Szmulewitz; Carrie W Rinker-Schaeffer
Journal:  Nat Rev Clin Oncol       Date:  2011-04-26       Impact factor: 66.675

5.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

6.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.

Authors:  Shuji Ogino; Gregory J Kirkner; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Aditi Hazra; Andrew T Chan; Reiko Dehari; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

7.  Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N Glickman; Cristina R Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

8.  A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Yoshifumi Baba; Saori Toyoda; Li Chen; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

9.  Tumor margin histology predicts tumor aggressiveness in papillary thyroid carcinoma: a study of 514 consecutive patients.

Authors:  Kuk-Jin Kim; Soon Won Hong; Yong Sang Lee; Bup-Woo Kim; Seung Chul Lee; Hang-Seok Chang; Cheong Soo Park
Journal:  J Korean Med Sci       Date:  2011-02-25       Impact factor: 2.153

10.  Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Xiao-Jun Wu; Ya Ding; Chun-Yan Li; Xing-Juan Yu; Xing Zhang; Zhi-Zhong Pan; De-Sen Wan; Li-Ming Zheng; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  BMC Cancer       Date:  2010-09-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.